Cargando…
ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer
Inhibitor of apoptosis protein (IAP) antagonists have shown activity in preclinical models of head and neck squamous cell carcinoma (HNSCC), and work across several cancer types has demonstrated diverse immune stimulatory effects including enhancement of T cell, NK cell, and dendritic cell function....
Autores principales: | Ye, Wenda, Gunti, Sreenivasulu, Allen, Clint T., Hong, Youji, Clavijo, Paul E., Van Waes, Carter, Schmitt, Nicole C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959437/ https://www.ncbi.nlm.nih.gov/pubmed/32002309 http://dx.doi.org/10.1080/2162402X.2019.1710398 |
Ejemplares similares
-
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021) -
The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
por: Knoll, Gertrud, et al.
Publicado: (2021) -
Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation
por: Gill, Catherine, et al.
Publicado: (2009) -
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
por: Darding, M, et al.
Publicado: (2011) -
Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression
por: Paschall, Amy V, et al.
Publicado: (2014)